Navigation Links
TrialNetworks Feasibility Survey™ App Gets ARIAD Pharmaceuticals Unprecedented 75% Response from Potential Clinical Trial Investigator Sites
Date:9/30/2013

ing the lives of cancer patients with breakthrough medicines.

Jeff Davis, Associate Director, Clinical Operations at ARIAD Pharmaceuticals, said, “ARIAD enjoys a strong collaboration with TrialNetworks and we were highly encouraged by the response we received using Feasibility Survey. Integrating these assessments into the rest of the platform ensures we realize the full benefits of TrialNetworks including more efficient processes, reduced time and cost, and a welcoming site experience. TrialNetworks technology makes it easy for sites to provide ARIAD with reliable information which we will use to make critical site selection decisions, and gives us clear visibility into and more control over global clinical operations than ever before.”

To prepare for the selection process, ARIAD sent the TrialNetworks Feasibility Survey to nearly 300 sites globally and received 225 responses – a huge accomplishment, says ARIAD Clinical Trial Manager Jay Pietrantonio: “The gold standard is to receive 50% of surveys back. To get 75% back is extremely impressive. The TrialNetworks Feasibility Survey app enabled ARIAD to meet our aggressive timeline for site selection by quickly identifying sites we are confident will enroll and exceed expectations in this pivotal trial.”

The TrialNetworks platform is the industry’s only Clinical Trial Optimization System proven to improve results from startup through closeout – including feasibility, site activation, patient recruitment and retention, site engagement and conduct – all from one centralized interface.

Eric Silberstein, CEO of TrialNetworks, said, “We are thrilled to partner with forward-thinking customers such as ARIAD who seek innovative solutions to make clinical operations more efficient. Equipping operations teams and sites with modern and efficient technology from feasibility through to closeout is becoming a critical success factor for sponsors and CROs.”

To discover how the TrialNetworks
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TrialNetworks Customer to Present Results of Using Site Engagement Technology to Improve Study Operations and Patient Enrollment at Clinical Trial Optimization Conference
2. MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCalls Microscope
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... The report expects global cell isolation and expansion ... provides a carefully analyzed data about the vital drivers, ... , Full Copy of Report @ http://bit.ly/1yUxy0T ... cell expansion will keep witnessing growth at an impressive ... be driven by rapid technological advancements, government funding and ...
(Date:12/24/2014)... 23, 2014 China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., ... the China Food and Drug Administration (the "CFDA") ... previously disclosed in the Company,s public filings, the ...
(Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical device ... to participate in the 19th Annual Piper Jaffray,Health Care ... on Tuesday,November 27, 2007. Steven G. Anderson, president ... beginning at approximately 1:30 p.m. EST. CryoLife,s live ...
... pm ET on November 27, 2007, CAMBRIDGE, Mass., ... today announced its participation,in the Lazard Capital Markets Fourth ... at the New York Palace Hotel in New York,City. ... be presenting at 2:00 pm ET on Tuesday, November ...
... Scientists have announced,that they successfully reprogrammed adult ... of patient-specific medical treatments and,research without the need ... the Discovery Institute,s Senior Fellow in Bioethics,and author ... hailed the,breakthrough as demonstrating that ethical science is ...
Cached Biology Technology:CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York 2Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference 2
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today ... audit to confirm its adherence to current U.S. ... enables HITLAB to conduct regulated smart device and ... for patient safety and research quality. ... quality, and delivery with innovative technology," said ...
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... from the north-central U.S. and beyond will convene in Kalamazoo, ... and discuss new science, expand on existing science, and explore ... a special emphasis on the Great Lakes. Events include a ... by William F. Ruddiman titled, "When Did We Transform Earth,s ...
... York, NY (April 18, 2013) An excess of ... psychosis in people who are at risk for schizophrenia, ... Center (CUMC) published in the current issue of ... diagnostic tool for identifying those at risk for schizophrenia ...
... IOF Medal of Achievement has been presented today to ... Department of Internal Medicine, Hospital del Mar, Director of ... Institute of Medical Research and Professor of Medicine at ... Foundation (IOF) awards the IOF Medal of Achievement every ...
Cached Biology News:Kalamazoo center of geologic focus this May 2High levels of glutamate in brain may kick-start schizophrenia 2IOF Medal of Achievement awarded to Professor Adolfo Diez-Perez 2
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. ID clarifier: tissue-culture treated ... cm 2 D H 245 ...
... Novagens PhageMaker System is optimized for maximum ... ligated with any bacteriophage l vector. Using a ... > 10^7 pfu/g arms (> 4 x 10^8 ... This one-tube system is extremely easy to use; ...
Mouse monoclonal [7B9] to beta II Tubulin ( Abpromise for all tested applications). Antigen: Synthetic peptide, CEEEEGEDEA found at the c-terminus of beta II tubulin. Entrez GeneID: 10383 ...
Polymerase (RNA) II (DNA directed) polypeptide L...
Biology Products: